Additionally, inhibition of the RAF-MEK-ERK pathway via mutant MEK demonstrates reversion of the cancer phenotype, and inhibitors of Raf kinase are targeted anti-tumor therapies [29]. This evidence concerns the gene MAP2K7 and neoplasm.